Abstract
Multiple sclerosis (MS), a chronic, unpredictable, and debilitating autoimmune disease of the central nervous system, can significantly impact patients' quality of life. Symptoms vary widely and range from mild to severe. Disease-modifying therapy, including monoclonal antibody (mAb) treatment, is the standard of care for MS because these agents slow the disease progression while reducing the frequency and severity of relapses. In MS, mAbs modulate the immune system to slow effects on the brain and spinal cord, and they are generally preferred because of their efficacy, favorable adverse-effect profiles, and dosing frequency. Recent research has focused on the development of novel therapies. Pharmacists can play various roles in MS management and mAb use, and their involvement will continue to grow as new therapies become available.